Is MKGAY.PK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

39 people get MKGAY.PK articles and Market Currents by email alert.

Get email alerts on MKGAY.PK »

HEADLINES:

Investing In Cancer Research Is Worth The Risk: Echo He
Life Sciences Report • Fri, May 24
Oncothyreon A Speculative Buy
Northwest Trader • Fri, May 17 • 4 Comments
Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy
Bioassociate Consulting • Thu, Mar 28 • 5 Comments
George Zavoico: Biotech Stocks That Deserve A Closer Look
Life Sciences Report • Fri, Mar 8 • 1 Comment
Threshold Pharmaceuticals: A Biotech Trading At Half Its Intrinsic Value
BPD Research • Mon, Mar 4 • 14 Comments
Stimuvax Trial Failure: A Value Opportunity In Oncothyreon
PropThink • Mon, Dec 24, 2012 • 5 Comments
3 Best Biotech Stocks For This Week (Part IV)
Jorge Aura • Wed, Oct 3, 2012 • 4 Comments
4 Market Moving Healthcare Stocks To Watch This Week
Ang Nguyen • Tue, Sep 18, 2012 • 3 Comments
3 Best Biotech Stocks For This Week (Part II)
Jorge Aura • Mon, Sep 17, 2012 • 11 Comments
3 Best Biotech Stocks For This Week (Part I)
Jorge Aura • Wed, Sep 12, 2012 • 15 Comments
Dr. Reddy's And Merck Serono Partner On Biosimilars
The Burrill Report • Sun, Jun 10, 2012
Dividends Made in Germany: A Review of Payouts of the DAX Index
Clemens Scholl • Wed, May 11, 2011 • 24 Comments
China Biotech Week in Review: Merck Plans Big Increase in China Sales
ChinaBio Today • Sun, Apr 3, 2011
Putting Biotechs Under the Microscope
Morningstar • Fri, Mar 11, 2011
To Partner or Not to Partner: That Is the Question
Michael Becker • Thu, Mar 10, 2011 • 13 Comments
GSK Sets Aside $3.4 Billion Over Avandia Liabilities: Biotech's Latest Tribulations
The Burrill Report • Sun, Jan 23, 2011
China Biotech Week in Review: China Track at J.P. Morgan Conference
ChinaBio Today • Sun, Jan 9, 2011
Advisory Votes Against Expanding Use of GSK’s, Merck’s Prostate Drugs: Biotech's Latest Tribulations
The Burrill Report • Sun, Dec 5, 2010
Japan’s Otsuka Plans Largest Biotech IPO in the World
The Burrill Report • Sun, Nov 14, 2010
Biotech Ends October With Almost $1B in IPOs, $3B in M&A Activity, $3B in Possible Partnerships
The Burrill Report • Sun, Oct 31, 2010

To learn more about Seeking Alpha Pro, click here.

EMD Serono Snags US license for Tesamorelin From Theratechnologies
Eben Tessari • Fri, Oct 31, 2008

Investing In Cancer Research Is Worth The Risk: Echo He
Life Sciences Report • Fri, May 24
Oncothyreon A Speculative Buy
Northwest Trader • Fri, May 17 • 4 Comments
Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy
Bioassociate Consulting • Thu, Mar 28 • 5 Comments
George Zavoico: Biotech Stocks That Deserve A Closer Look
Life Sciences Report • Fri, Mar 8 • 1 Comment
Threshold Pharmaceuticals: A Biotech Trading At Half Its Intrinsic Value
BPD Research • Mon, Mar 4 • 14 Comments
Stimuvax Trial Failure: A Value Opportunity In Oncothyreon
PropThink • Mon, Dec 24, 2012 • 5 Comments
3 Best Biotech Stocks For This Week (Part IV)
Jorge Aura • Wed, Oct 3, 2012 • 4 Comments
4 Market Moving Healthcare Stocks To Watch This Week
Ang Nguyen • Tue, Sep 18, 2012 • 3 Comments
3 Best Biotech Stocks For This Week (Part II)
Jorge Aura • Mon, Sep 17, 2012 • 11 Comments
3 Best Biotech Stocks For This Week (Part I)
Jorge Aura • Wed, Sep 12, 2012 • 15 Comments
Dr. Reddy's And Merck Serono Partner On Biosimilars
The Burrill Report • Sun, Jun 10, 2012
Dividends Made in Germany: A Review of Payouts of the DAX Index
Clemens Scholl • Wed, May 11, 2011 • 24 Comments
China Biotech Week in Review: Merck Plans Big Increase in China Sales
ChinaBio Today • Sun, Apr 3, 2011
Putting Biotechs Under the Microscope
Morningstar • Fri, Mar 11, 2011
To Partner or Not to Partner: That Is the Question
Michael Becker • Thu, Mar 10, 2011 • 13 Comments
GSK Sets Aside $3.4 Billion Over Avandia Liabilities: Biotech's Latest Tribulations
The Burrill Report • Sun, Jan 23, 2011
China Biotech Week in Review: China Track at J.P. Morgan Conference
ChinaBio Today • Sun, Jan 9, 2011
Advisory Votes Against Expanding Use of GSK’s, Merck’s Prostate Drugs: Biotech's Latest Tribulations
The Burrill Report • Sun, Dec 5, 2010
Japan’s Otsuka Plans Largest Biotech IPO in the World
The Burrill Report • Sun, Nov 14, 2010
Biotech Ends October With Almost $1B in IPOs, $3B in M&A Activity, $3B in Possible Partnerships
The Burrill Report • Sun, Oct 31, 2010

There are no Transcripts on MKGAY.PK.

There are no News articles on MKGAY.PK.

MKGAY.PK vs. ETF Alternatives

Company Description

Currently, there's no company description for MKGAY.PK.

Sector: Healthcare

Industry: Drug Related Products

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, December 19, 2012, 8:39 AM Stimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR) Comment! [On the Move, Healthcare]
Tuesday, October 16, 2012, 9:01 AM Threshold Pharmaceuticals (THLD) jumps 13.5% after the FDA reaches an agreement for the Phase III trial of TH-302 for the treatment of pancreatic cancer. The study will be conducted by Germany's Merck, Threshold's partner in the development of TH-302. (PR) Comment! [Healthcare, On the Move]
Friday, November 18, 2011, 3:55 PM ADRs of German chemical and pharmaceutical maker Merck KGaA (MKGAY.PK +0.7%) get a lift after receiving a positive opinion from a committee of the European Medicines Agency for its application to extend the indication of Rebif, its leading treatment for relapsing forms of multiple sclerosis. Comment! [Global & FX, Healthcare, On the Move]
Wednesday, July 27, 2011, 3:09 AM Merck KGaA (MKGAF.PK) reports a Q2 net EPS loss of €0.40 ($0.58), vs. profit of €0.84 a year earlier. Revenue +16% to €2.56B. For 2011, Merck expects operating profit of about €1B, below guidance given in April, due to one-time adjustments. 2 Comments [Earnings, Healthcare]

MKGAY.PK Merck Kgaa Unsp Adr

MKGAY.PK

Merck Kgaa Unsp Adr